Nurix Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview

Nurix Therapeutics

23/01/2023 11:48

* Nurix Therapeutics Inc  NRIX.OQ   NRIX.O  is expected
to show a
rise in quarterly revenue when it reports  results on January 25
(estimated). 
    * The San Francisco California-based  company is expected to
report  a 132.2% increase in revenue to $17.171 million from
$7.4 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Nurix Therapeutics
Inc is
for a loss of 79 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nurix
Therapeutics Inc is $35​, above​ its last closing price
of $12.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Aug. 31 2022  -0.96       -0.98      -0.90     Beat    7.7
 May. 31 2022  -0.98       -0.99      -1.01     Missed  -2.4
 Feb. 28 2022  -0.89       -0.88      -0.95     Missed  -8.5​
 Nov. 30 2021  -0.69       -0.69      -0.85     Missed  -22.5
 ​​Aug.        -0.66       -0.63      -0.65     Missed  -2.9
 31 2021                                                
 May. 31 2021  -0.54       -0.54      -0.60     Missed  -10.4​
 Feb. 28 2021  -0.46       -0.46      -0.63     Missed  -37.6
 Nov. 30 2020  -0.51       -0.54      -0.51     Beat    5.2
 This summary was machine generated January 23 at 11:48 GMT.  All
figures in US dollars  unless otherwise stated